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Abstract
Increased platelet aggregation is one of the major risk factors for cardiovascular events. However, recent studies have 
demonstrated the inhibition of platelet aggregation by omega-3 PUFAs. The aim of this work was to study the effect of the addition 
of omega-3 PUFAs to the combination of aspirin and clopidogrel on the platelet aggregation in patients with coronary heart disease. 
In all, 40 patients with coronary heart disease and diabetes mellitus type 2 undergoing PCI with stent implantation were included in 
the study. Clopidogrel in a 300 mg loading dose was given after drawing blood for baseline measurement of ADP-induced platelet 
aggregation. Patients were randomized into two groups. The first group included 20 patients who received 75 mg clopidogrel once 
daily, 100 mg aspirin once daily and 1000 mg omega-3 PUFAs daily. The second group included 20 patients who received 75 
mg clopidogrel once daily and 100 mg aspirin daily. The ADP– induced platelet aggregation was performed twice, once before 
clopidogrel administration and once after one month. All the patients were genotyped for CYP2C19 polymorphism. No significant 
differences were noted among the genotype and allele frequencies of the cytochrome CYP2C19 gene between the two groups. The 
addition of omega-3 PUFAs to the standard dual antiplatelet therapy of aspirin and clopidogrel significantly decreased the ADP-
induced platelet aggregation. 
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Introduction
The standard treatment for patients with acute coronary 
syndrome involves a combination of dual-antiplatelet therapy, 
aspirin and thienopyridine, which has been proven efficacious 
in reducing the rate of recurrent cardiac events, including 
stent thrombosis [1,2].  However, there is a significant inter-
individual variability in response to these two drugs. The results 
from several studies have shown that the CYP2C19 gene 
polymorphism (CYP2C19*2) was associated with a higher 
platelet reactivity in patients on clopidogrel, which in turn 
has been linked to a worsened clinical outcome post coronary 
stenting [3]. 
 Over the last few years, interest in the role of omega-3 
polyunsaturated fatty acids (PUFAs) in the prevention and 
management of cardiovascular disease has increased. In the 
GISSI-Prevenzione trial, supplementation with the intake 
of one fish oil capsule daily was shown to reduce the risk of 
sudden death in patients with recent myocardial infarction [4]. 
The mechanisms of the beneficial effect of omega-3 PUFAs on 
cardiovascular disease are multifactorial.
Increased platelet aggregation is one of the major risk 
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factors for cardiovascular events. However, recent studies have 
demonstrated the inhibition of platelet aggregation by omega-3 
PUFAs [5]. 
The aim of our investigation was to study the effect of the 
addition of omega-3 PUFAs to the combination of aspirin and 
clopidogrel on platelet aggregation in patients with coronary 
heart disease. 
Materials and methods
Totally, 40 patients with coronary heart disease and 
diabetes type 2 undergoing PCI with stent implantation were 
included in the study. Clopidogrel, in a 300 mg loading dose, 
was given after blood collection for baseline measurement of 
ADP-induced platelet aggregation. All the patients received 
beta-blockers, nitrates, ACE-inhibitors and statins. Patients 
were randomized into two groups. 
The  first  group  included  20  patients  who  received 
clopidogrel 75 mg once daily, aspirin 100 mg once daily and 
omega-3 PUFAs (Atheroblok, “Actavis”) 1000 mg daily. 
The second group included 20 patients who received 
clopidogrel 75 mg once daily and aspirin 100 mg daily.
Then, ADP–induced platelet aggregation was performed 
twice, once before clopidogrel administration and once after one 
month.
All the patients were genotyped for CYP2C19 
polymorphism. The polymerase chain reaction was performed 
using the oligonucleotide primers to determine A681G 
polymorphism of the CYP2C19 gene [6]:
5’-CAGAGCTTGGCATATTGTATC-3’
5’-GTAAACACACAAAACTAGTCAATG-3’
Results: 
The frequencies of the genotypes and alleles of the 
CYP2C19 gene are shown in Table 1.
No significant differences were noted among the genotype 
and allele frequencies of the cytochrome CYP2C19 gene 
between the two groups.
The baseline ADP-induced platelet aggregation in the first 
group was     77.76±2.7%, while in the second group it was 
79.5 ± 1.7 % (p>0.05). After one month of therapy, the level 
of ADP-induced platelet aggregation decreased significantly in 
both groups  to 60.5±2.9% in the first group and 69.3± 2.8% in 
the second group; however, in the first group, which had been 
receiving omega-3 PUFAs (Atheroblok), the ADP-induced 
platelet  aggregation  was  lower  by  8.8%  compared  with  the 
second group. 
 No association between CYP2C19 gene genotypes and 
the levels of ADP-induced platelet aggregation was observed in 
these patients. 
Discussion
Our study indicates that the triple therapy with aspirin, 
clopidogrel, and omega-3 PUFAs decreased the platelet ADP-
induced aggregation more effectively than the standard dual 
antiplatelet therapy.
Recently, Grzegorz Gajos et al., demonstrated that the 
addition of omega-3 PUFAs to the combination of aspirin 
and  clopidogrel  significantly  potentiated  platelet  response  to 
clopidogrel post percutaneous coronary intervention [5].
The mechanisms of the favorable antithrombotic effects 
of omega-3 PUFAs are complex. Not only do they have a 
membrane stabilizing effect, there is also a competition of 
omega-3 PUFAs for cyсlooxygenase activity with arachidonic 
acid, which lowers the production of the platelet-activating 
eicosanoids (e.g. thromboxane A2), which in turn play an 
important role [7]. In a study in diabetic patients, Woodman 
et al. demonstrated the administration of omega-3 PUFAs was 
associated with a 30% decrease in platelet aggregability [8].
Conclusion 
The addition of omega-3 PUFAs to the standard dual 
antiplatelet therapy with aspirin and clopidogrel significantly 
decreased the ADP-induced platelet aggregation.
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